Avoid common mistakes on your manuscript.
Correction to: Adv Ther (2019) 36:1786–1811 https://doi.org/10.1007/s12325-019-00985-8
In this article, the drug name in figure 2 is given as Atorvastatin 20 mg incorrectly. The correct Fig. 2 is given below.
The Tables 1 and 2 consists few errors in published article. The correct Tables 1 and 2 are given below.
In the result section of abstract, text has been updated. The incorrect text is “In the 11 cases, mean baseline LDL-C was 419 ± 74.6 mg/dL and was markedly reduced by lomitapide to a nadir of 176.7 ± 46.3 mg/dL (58.4 ± 6.8% decrease). Six patients achieved recommended target levels for children below 135 mg/dL, five of whom had LA frequency reduced.”
The correct text is “In the 11 cases, mean baseline LDL-C was 422 ± 245.4 mg/dL and was markedly reduced by lomitapide to a nadir of 192.2 ± 163.2 mg/dL (56.7 ± 21.7% decrease). Six patients achieved recommended target levels for children below 135 mg/dL, three of whom had LA frequency reduced and a further three stopped LA.”
In the section of Summary of the Case Series, text has been updated. The incorrect text is “Table 2 provides summary descriptive statistics for all 11 patients. Baseline LDL-C was 419.9 ± 74.6 mg/dL. The mean at nadir was 176.7 ± 46.3 mg/dL, representing a 58.4 ± 6.8% reduction in LDL-C. Note that patients 9–11 had modest decreases in LDL-C levels (patient 9 was treated to reduce LA frequency, and patients 10 and 11 had compliance issues). These LDL-C reductions were achieved with a mean dose of lomitapide 24.5 ± 4.3 mg/day over a mean period of 20.0 ± 2.9 months.”
The correct text is “Table 2 provides summary descriptive statistics for all 11 patients. Baseline LDL-C was 422.7 ± 245.4 mg/dL. The mean at nadir was 192.2 ± 163.2 mg/dL, representing a 56.7 ± 21.7% reduction in LDL-C. Note that patients 9–11 had modest decreases in LDL-C levels (patient 9 was treated to reduce LA frequency, and patients 10 and 11 had compliance issues). These LDL-C reductions were achieved with a mean dose of lomitapide 25.0 ± 13.8 mg/day over a mean period of 20.0 ± 2.9 months.”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Ben-Omran, T., Masana, L., Kolovou, G. et al. Correction to: Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. Adv Ther 41, 1765–1769 (2024). https://doi.org/10.1007/s12325-023-02739-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-023-02739-z